Targeted drug shows promise in cervical cancer

The epidermal growth factor receptor (EGFR) inhibitor erlotinib appears to be effective in locally advanced cervical cancer, Brazilian researchers have found in a breakthrough study.

Published online today in Cancer, the study involved 36 women with stage IIB to IIIB epidermoid cervical cancer who were given erlotinib at a dose of 150mg/day one week before and in combination with cisplatin-based chemoradiation.

All but two of the patients achieved a complete response, with two and three-year overall survival rates of 92% and 80%,